| Literature DB >> 28107692 |
Ayuna Hattori1, Daniel McSkimming1, Natarajan Kannan1, Takahiro Ito2.
Abstract
FLT3 is frequently mutated and overexpressed in acute myelogenous leukemia (AML) and other hematologic malignancies. Although signaling events downstream of FLT3 receptor tyrosine kinase have been studied in depth, molecular mechanisms of how FLT3 expression is regulated at the post-transcriptional level in particular remain elusive. In this study, we investigated the roles of an RNA binding protein MSI2 as a regulator of FLT3 expression. MSI2 and FLT3 are significantly co-regulated in human AML and chronic myelogenous leukemia in blast crisis (BC-CML). Genetic loss of MSI2 leads to down-regulation of the FLT3 receptor in both AML and BC-CML cells and concomitant impairment of clonogenic growth potential. Furthermore, we demonstrate that MSI2 protein is physically bound to FLT3 mRNA transcripts, suggesting post-transcriptional control of FLT3 expression. Collectively, these results reveal a novel mode of FLT3 regulation essential for leukemia growth, which may aid in designing a targeted therapy to treat human myeloid leukemia.Entities:
Keywords: Acute myelogenous leukemia; Chronic myelogenous leukemia; FLT3; Post-transcriptional regulation; RNA binding proteins
Mesh:
Substances:
Year: 2017 PMID: 28107692 PMCID: PMC5508866 DOI: 10.1016/j.leukres.2017.01.015
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156